Andrew Hirsch, President & CEO at C4 Therapeutics (NASDAQ:CCCC), reported a large acquisition of company stock options on September 19, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Hirsch, President & CEO at C4 Therapeutics, a company in the Health Care sector, was just awarded stock options worth 489,600 shares of CCCC. The options give Hirsch the right to buy the company's stock at $2.15 per share.
C4 Therapeutics shares are trading up 0.68% at $2.23 at the time of this writing on Wednesday morning. Since the current price is $2.23, this makes Hirsch's ...